

# Sampling Uncertainty and Patient-Level Cost-Effectiveness Analysis (Part 1b)

Henry A. Glick, Ph.D.

EPI 550

April 22, 2020



---

---

---

---

---

---

---

---

# Confidence Interval for Incremental Cost-Effectiveness Ratio



---

---

---

---

---

---

---

---

# "Counting" Method 2: CI for ICER

- Can also determine fraction of results that fall on one side of W by identifying slopes of 0, 1, or 2 lines through the origin that exclude  $\alpha/2$  of distribution
  - Identify them by either counting/estimating distribution of results falling on each side of lines through origin
    - Slopes of lines that have 2.5% of distribution on 1 side and 97.5% on other define 95% CL for ICER
    - Slopes of these lines define values of W for which acceptability curve has heights of 2.5% and/or 97.5%
- Referred to as confidence interval for cost-effectiveness ratio



---

---

---

---

---

---

---

---

### Construction of CI for Difference, OR, or RR

- Common algorithm
  - Develop distribution of difference (e.g., NMB), OR, or RR
    - e.g, create empiric distribution from bootstrap or assume a distribution such as normal or log normal
  - Order distribution from smallest to largest
  - Construct 95% CI by identifying 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles of rank-ordered distribution
    - Either by counting (nonparametric) or estimating density (parametric)
  - Values of outcome that bound these percentiles represent the 95% confidence limits
- Works well for differences, OR, or RR



---

---

---

---

---

---

---

---

### Construction of CI for ICER

- To use same algorithm for construction of CI for ICER:
  - Develop joint distribution of difference in C and Q and calculate ratios
  - Order ratios from smallest to largest (referred to as “naive ordering”)
  - For 95% CI, identify 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles of rank-ordered ratios
  - Values of ratios that bound 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles represent 95% confidence limits



---

---

---

---

---

---

---

---

### All of Density on One Side of Y-Axis

- Algorithm for constructing CI for ICER WORKS when all density/replicates are on ONE SIDE of Y-axis
- On CE plane, interval stretches COUNTER-CLOCKWISE from lower (CLOCKWISE) limit to upper (COUNTER-CLOCKWISE) limit



---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---


---

---

---

---

Lower 95% Confidence Limit (Slide 44, Part 1A)




---

---

---

---

---

---

---

---


---

---

---

---

Upper 95% Confidence Limit (Slide 46, Part 1A)




---

---

---

---

---

---

---

---


---

---

---

---

95% CI for ICER for Experiment 1




---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

Confidences Statements for CI for ICER

- Not confident of value if:
  - $LL < W < UL$
- Confident of value if:
  - $LL < UL < W$  (confident of good value)
  - $W < LL < UL$  (confident of bad value)




---

---

---

---

---

---

---

---

Confidences Statements for Current Experiment

- Can be confident of value when W not included in confidence interval
- **When lower limit is a smaller number than upper limit**
  - Interval ranges between lower and upper limit  
28,200 to 245,200
  - Confident of value if WTP is either smaller than lower limit or greater than upper limit
    - Confident of bad value if  $WTP < 28,200$ 
      - Because at least 97.5% of samples have ratios greater than 28,200
    - Confident of good value if  $WTP > 245,200$ 
      - Because at least 97.5% of samples have ratios less than 245,200




---

---

---

---

---

---

---

---

“Common” Conclusions, CI for ICER

W	What is often said
<28,200	“95% confident Rx A not good value” (Rx B good value)
76,800	Can’t be 95% confident value of Rxs differs
100,000	Can’t be 95% confident value of Rxs differs
127,700	Can’t be 95% confident value of Rxs differs
>245,200	“95% confident Rx A good value (Rx B not good value)”

- Usually employ 2-tailed interpretation of CI for ICER




---

---

---

---

---

---

---

---

## Confidence Interval for NMB



---

---

---

---

---

---

---

---

## “Counting” Method 3: CI for NMB

- Can determine if  $W$  falls inside or outside distribution by constructing distribution of NMB for specified  $W$  and identifying whether 0 falls within interval
- As for any difference, construct interval by ordering distribution of NMB and identifying values of NMB that define the 2.5th and 97.5th percentiles
- In contrast with acceptability curve and CI for ICER, not (typically) defining lines through the origin of CE plane
  - But lines through origin have same meaning as for acceptability curves and CI for ICER



---

---

---

---

---

---

---

---

## NMB Recap

$$\text{NMB} = (W \cdot \Delta Q) - \Delta C$$

- For a WTP of 50,000, NMB for experiment 1:  
 $(50,000 \cdot .01) - 1000 = -500$
- Study result a difference in means of net benefits, not a ratio of means, and is always defined (i.e., no odd statistical properties like ratio) and continuous
- Unlike cost-effectiveness ratio, standard error of net benefits is always defined
- Given not all decision making bodies have agreed upon maximum willingness to pay, routinely estimate net benefit over range of policy relevant values of willingness to pay



---

---

---

---

---

---

---

---

### Net Benefit Graphically

- For a given W, can calculate value of NMB for every point on CE plane
- Formula: For replicate "i"  $NMB = W \Delta Q_i - \Delta C_i$
- If W= 50,000, following points all fall on same NMB line (slope 50,000, intercept -500) and have same NMB value

$\Delta C$	$\Delta Q$	NMB
-500	0	$(50,000 * 0) - (-500) = 500$
49,500	1	$(50,000 * 1) - (49,500) = 500$
99,500	2	$(50,000 * 2) - (99,500) = 500$
149,500	3	$(50,000 * 3) - (149,500) = 500$

- Value of NMB for lines with 50,000 slope = -intercept  
– e.g.,  $-(-500) = 500$




---

---

---

---

---

---

---

---

---

---

### Net Benefit Graphically (2)

- As with diagnostic test optimal operating slopes, NMB graphically defined on cost effectiveness plane using a family of lines
- Each line has a slope equal to W
- Each line represents a single value of NMB which equals  $-\Delta C$  (i.e., - intercept, because when  $\Delta Q=0$ ,  $W\Delta Q$  drops out of equation)
- 95% CI for NMB defined by identifying 2 NMB lines that each omit 2.5% of distribution




---

---

---

---

---

---

---

---

---

---

### Net Benefit Graphically (3)

- As we just saw, following 4 points all fall on same NMB line when W=50,000
- If W= 100,000, the same 4 points all fall on different NMB lines (slope 100,000, varying intercepts) and have different values of NMB

$\Delta C$	$\Delta Q$	NMB
-500	0	$(100,000 * 0) - (-500) = 500$
49,500	1	$(100,000 * 1) - (49,500) = 50,500$
99,500	2	$(100,000 * 2) - (99,500) = 100,500$
149,500	3	$(100,000 * 3) - (149,500) = 150,500$

- Value of NMB for lines with 100,000 slope = -intercept




---

---

---

---

---

---


---

---

---

---






---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

- ### Confidences Statements for CI for NMB
- If both confidence limits negative, 95% confident therapy is bad value
    - i.e., for values of WTP  $\leq 28,200$
  - If both confidence limits positive, 95% confident therapy is good value
    - i.e., for values of WTP  $\geq 245,200$
  - If one confidence limit positive and one negative, cannot be 95% confident value of 2 therapies differs
    - i.e., for values of WTP  $> 28,200$  and  $< 245,200$

---

---

---


---

---

---

---

---




---

---

---

---


---

---

---

---

CI for ICER, CI for NMB, Acc Curve All Use Same Lines




---

---

---

---

---

---

---

---

Similarities and Differences

- For magnitude estimation for a single value of W, NMB provides information that is NOT shared by acceptability curve or CI for ICER
  - i.e., generally isn't identifying lines through origin as are acceptability curve and CI for ICER
- For meta-question about ranges of W for which we can or can't be confident of value, NMB graph provides information that IS shared
  - Nonparametrically, identification of whether CI for NMB includes or excludes 0 relies on same lines through origin as acceptability curve and CI for ICER
  - Parametrically, CI for NMB and acceptability curve use transformation of Fieller's theorem equation for CI for ICER




---

---

---

---

---

---

---

---

Acceptability & CI for ICER

- Acceptability curve plots confidence intervals for the cost-effectiveness ratio
  - e.g., the value of WTP where the height of the acceptability curve equals 0.025 and/or 0.975 represent the 95% confidence limits for the cost-effectiveness ratio
    - In current example, 95% CL = 28,200 and 245,200




---

---

---

---

---


---

---

---

### Acceptability & CI for NMB

- Acceptability curves also report values of WTP for which one of NMB confidence limits equals 0
  - e.g. if we calculate NMB using values of WTP where height of acceptability curve equals 0.025 and/or 0.975, one of 95% confidence limits for NMB will equal 0
  - If we calculate NMB using values of WTP where height of the acceptability curve equals 0.25 and/or 0.75, one of 50% confidence limits for NMB will equal 0




---

---

---

---


---

---


---

---


### Review of Results for Experiment 1




**Acceptability curve**  
Acceptability curve intersects 0.025 and 0.975 at 28,200 and 245,200



**Confidence interval for ICER**  
CER CI: (28,200 to 245,200)



**Confidence frontier for NMB**  
CI intersect decision threshold (0) at 28,200 and 245,200



---

---

---

---

---


---

---

---

### “Pattern 1” Findings

- Refer to findings like experiment 1's as pattern 1 findings
- Occur when difference in effect is significant
- Know we are observing pattern 1 finding when:
  - Confidence interval for cost-effectiveness ratio excludes Y axis (i.e.,  $LL < PE < UL$ )
  - Both NMB confidence limits curves intersect decision threshold (0) once
  - Acceptability curve intersects horizontal lines drawn at both 0.025 and 0.975




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

### Confidence vs Value of Information

- Requiring statistical significance (i.e., confidence) prior to the adoption of a new therapy that maximizes NMB runs counter to expected utility theory
  - Said to impose opportunity costs on patients

---

---

---

---

---

---

---

---

### Quality of the Evidence

- Rejection of significance tests for cost-effectiveness ratios/NMB does not imply that decisions should be made using point estimates alone
  - Particularly if a decision can be made to collect more information
- “Value of information” represents difference in expected value of outcome given current decision and expected value of outcome that would result if we had perfect information (EVPI)
  - Determined based on probability decision is wrong and costs of wrong decision if it occurs




---

---

---

---

---

---

---

---

### Per-Person Expected Value of Perfect Information

$$EVPI_{PP} = \min(V_j, V_k)$$

where

$$V_j = \forall_j NMB_j > 0: \frac{N_j}{N} \sum \frac{NMB_j}{N_j}$$

$$V_k = \forall_k NMB_k < 0: \text{abs} \left( \frac{N_k}{N} \sum \frac{NMB_k}{N_k} \right)$$




---

---

---

---


---

---

---

---

### Calculating Per-Person EVPI, 28,200




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---


---

---

---

---






---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

### Per Person EVPI

- Can be large because either there is a lot of uncertainty or because cost of mistakes (i.e., W) is large
  - e.g., might already be very certain (e.g., 99.99% confident), but if cost of mistakes is extremely high might want even greater certainty
- Can be small because either there is a lot of certainty or because costs of mistakes are small
  - e.g., might be very uncertain (e.g., only 10% confident), but if the cost of mistakes is extremely low, might not need greater certainty



---

---

---

---

---

---

---

---

### Total EVPI

- Total EVPI =  $N * EVPI_{pp}$ 
  - where N = number of people for whom treatment is indicated
- Net EVPI = Total EVPI - Cost of gathering additional information
- Given additional research is unlikely to yield perfect information, net EVPI at best provides upper bound on how much additional research should be funded
  - Need to focus on value of expected change in information
- Can also be used to evaluate particular uncertainties for which research is needed: expected value of perfect information for a parameter (EVPPi)



---

---

---

---

---

---

---

---

### Potential VOI Caveat

- "...value of information methods require consideration of the totality of the evidence base..."
- "...may not therefore be appropriate to simply base value of information estimates on the sampling variability from a single study where other studies exist."



---

---

---

---

---

---

---

---

### Asserted EVPI Advantages

- Quantitative measure of when we have enough information to make a decision
- Avoids inference
- Avoids temptation to use 'need for evidence' to delay decision making
- Recognises information gathering is not costless
- Can distinguish value of different types of information which might guide study design



---

---

---

---

---

---

---

---

### Rejection of Inference Applies to Everything

- Nothing different about economic decisions and other decisions
  - If we adopt an EVPI decision criterion – i.e., reject an inference criterion – for making economic decisions about therapies, should do same for other decisions
    - FDA should stop requiring significance for drug adoption decisions
- Economics (theoretical) vs medical (life and death) decision making?
- Significance testing may be transactionally efficient
  - Assuming there are costs of switching therapies, interpret significance tests as a mechanism for limiting switching and reducing these costs
    - Can build these (and other costs) into EVPI



---

---

---

---

---

---

---

---

### Acceptability Curves When More Than 2 Therapies



---

---

---

---


---

---

---

---

### Acceptability Curves When More than 2 Therapies



- When comparing more than 2 therapies, common to graph one curve per therapy with curves representing proportion of time therapy is best value (e.g., for Rx1: fraction that Rx1 > Rx2 AND Rx1 > Rx3)




---

---

---

---

---

---

---

---

---

---

### Counting Methods

- Calculate MB for each Rx using WTP; count MBs where Rx 1's MB greater than both Rx 2's and Rx 3's
- Calculate NMB for 1 vs 2, 1 vs 3, and 2 vs 3 using WTP; count NMBs where Rx 1's NMB vs Rx 2  $\geq 0$  AND Rx 1's NMB vs Rx 3  $\geq 0$




---

---

---

---

---

---

---

---

---

---

### Violation of Independence of Irrelevant Alternatives

- Best criterion violates Independence of irrelevant alternatives (IIA)
  - IIA a ubiquitous assumption in welfare economics / social choice theory
- IIA: Choice between alternatives x and y depends on preferences for x and y only (and is not affected by preferences for z)
  - e.g., if Rx 1 is chosen over Rx2 and Rx3, Rx1 must be both better than Rx2 and better than Rx3
- Focusing solely on fraction of time a therapy is best throws away information about the preference between 2 therapies (e.g., x and y) when a third therapy (e.g., z) is best




---

---

---

---

---

---

---

---

---

---

### Fraction of Time Best

- Suppose making choice for 7 people between 3 mutually exclusive modes of travel. Choose single mode for all 7
  - buses (B), cabs (C), or walking trails (W)
- Suppose most preferred choices are as follows:

Obs	1	2	3	4	5	6	7
Pref	W	W	W	B	B	C	C

- If basing decision solely on first preferences, heights of “multi-way” acceptability curves would equal:
  - walk, 3/7; bus, 2/7; cab, 2/7
    - i.e., walking is “best”




---

---

---

---

---

---

---

---

### Fraction of Time Better Value

- Suppose people who prefer cabs or buses least prefer walking; people who prefer walking least prefer cabs.
- Rank-ordered preferences would be:

Obs	1	2	3	4	5	6	7
1 <sup>st</sup>	W	W	W	B	B	C	C
2 <sup>nd</sup>	B	B	B	C	C	B	B
3 <sup>rd</sup>	C	C	C	W	W	W	W

- B is preferred to both W (4/7) and C(5/7)
- C is preferred to W (4/7), but not B (2/7)
- W is least preferred (3/7 against both B and C)




---

---

---

---

---

---

---

---

### Summary

- According to best rule, W is best and indifferent between B and C
- If instead consider complete set of preferences:
  - B preferred to both W and C
  - C preferred to W




---

---

---

---

---

---

---

---

### What's the Alternative

- Return to use of multiple pairwise comparisons
  - Strong tradition in economic choice theory, e.g., basis of Arrow impossibility theorem
- Analog to “best” algorithm is to select therapy that in pair-wise comparison is better than all other therapies
  - ??? Significantly better ???




---

---

---

---

---

---

---

---

### What's the Alternative (2)

- For each value of WTP plot lowest percentage acceptable against all other therapies
  - If B better than W 4/7 of time and better than C 5/7, height of B curve = 4/7
  - If C better than B 3/7 of time and better than W 4/7, height of C curve = 3/7
  - If W better than both B and C 3/7 of time, height of W curve = 3/7
- Best alternative has highest curve
  - i.e., select B because it is better than other 2 options at least 4/7 of the time
- Note, sum of heights of curves >1




---

---

---

---

---

---

---

---

### Example For Single Value of W

- Assume 4 Rx, 1-4; WTP = 1900  
 Fraction of times NMB for Rx (row identifiers in column 1) exceeds NMB for other Rx (column identifiers)

	Rx 1	Rx 2	Rx 3	Rx 4	BEST
Rx 1	--	<b>0.215</b>	0.5825	0.737	0.1875
Rx 2	<b>0.785</b>	--	<b>0.872</b>	<b>0.914</b>	<b>0.7015</b>
Rx 3	0.4175	<b>0.128</b>	--	0.7685	0.075
Rx 4	0.263	<b>0.086</b>	0.2315	--	0.036

Accomp.dta, cost and q11 variables

- Rx 2 better than Rx 1 78.5% of time, than Rx 3 87.2% of time, and Rx 4 91.4% of time
- Rx 2 better curve has height of 0.785 for W=1900




---

---

---

---

---

---

---

---

### Simulation

	Rx1	Rx2	Rx3
Cost	5000 (5000)	10,000 (2500)	16000 (2500)
QALY	0.5 (0.3)	0.6 (0.2)	0.7 (0.2)

	C1	C2	C3	Q1	Q2	Q3
C1	1.0					
C2	-0.9	1.0				
C3	-0.9	0.9	1.0			
Q1	0.9	-0.9	-0.9	1.0		
Q2	-0.9	0.9	0.9	-0.9	1.0	
Q3	-0.9	0.9	0.9	-0.9	0.9	1.0




---

---

---

---

---

---


---

---

---

---

### Multi-way Curve Simulation, Best Curves



- Rx1 "best" for W between 0 and 97,500 (red dashed line)
- Rx2 never "best" (green dashed line)
- Rx3 "best" for W greater than 97,500 (blue dashed line)




---

---

---

---

---

---


---

---

---

---

### Multi-way Curve Simulation, Better Frontier



- While Rx2 never "best", between 53K and 60K it is better (green solid line) than both Rx1 and Rx3




---

---

---

---

---

---


---

---

---

---

### Multi-way Curve Simulation, Better Frontier (2)



- While Rx1 “best” for W up to 97,500 (red dashed line), Rx3 (solid blue line) better than both Rx1 and Rx2 for W>60K




---

---

---

---

---

---

---

---

---

---

### Counting Methods

- MB:
  - Calculate MB for each Rx using WTP
  - Count MBs where Rx 1’s MB greater than Rx 2’s
  - Count MB’s where Rx 1’s MB greater than Rx3’s
  - Height of curve equals minimum of 2 fractions
- NMB:
  - Calculate NMB for Rx 1 vs 2, Rx 1 vs 3, and Rx 2 vs 3 using WTP
  - Count NMBs where Rx 1’s NMB greater than Rx 2’s
  - Count NMBs where Rx 1’s NMB greater than Rx 3’s
  - Height of curve equals minimum of 2 fractions




---

---

---

---

---

---

---

---

---

---

### In Usual Practice...

- While example suggests differences can be dramatic, for typical kinds of results, 2 approaches probably have similar recommendations over wide ranges of W
- However:
  - Can observe differences around boundaries between therapies
  - Compared to “Best” algorithm, “Better” algorithm yields more appropriate measure of magnitude of probability therapy is better than alternative




---

---

---

---

---

---


---

---

---

---






---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---